Down 18.1% in 4 Weeks, Here's Why KORU Medical Systems, Inc. (KRMD) Looks Ripe for a Turnaround

The heavy selling pressure might have exhausted for KORU Medical Systems, Inc. (KRMD) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

Zacks Investment Research • Feb 12, 2026

KORU Medical Systems, Inc. (KRMD) Soars 5.6%: Is Further Upside Left in the Stock?

KORU Medical Systems, Inc. (KRMD) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Zacks Investment Research • Feb 3, 2026

KORU Medical Systems Receives FDA 510(k) Clearance for Delivery of RYSTIGGO® (rozanolixizumab-noli), Expanding Label for FreedomEDGE® Infusion System

MAHWAH, N.J.--(BUSINESS WIRE)--KORU Medical Systems, Inc. (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, today announced that the Company received U.S. Food and Drug Administration (FDA) clearance for use of the KORU Medical FreedomEDGE® infusion system to deliver RYSTIGGO® (rozanolixizumab-noli), a therapy comme.

Business Wire • Jan 29, 2026

All You Need to Know About KORU Medical Systems, Inc. (KRMD) Rating Upgrade to Buy

KORU Medical Systems, Inc. (KRMD) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Zacks Investment Research • Jan 21, 2026

KORU Medical Systems Reports Preliminary Q4 and Full Year 2025 Results; Achieves Record Revenue and Full Year Positive Operating Cash Flow

MAHWAH, N.J.--(BUSINESS WIRE)--KORU Medical Systems (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, today announced preliminary unaudited results for the fourth quarter and full year ended December 31, 2025. Financial Results (unaudited) Preliminary, unaudited fourth quarter 2025 net revenues expected to be $10.9.

Business Wire • Jan 12, 2026

3 MedTech Stocks That Crushed the S&P 500 Over the Past Year

TransMedics, KORU Medical Systems and Cardinal Health beat the S&P 500 as execution, earnings visibility and company-specific catalysts drove gains.

Zacks Investment Research • Jan 9, 2026

KORU Medical Systems Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

MAHWAH, N.J.--(BUSINESS WIRE)--KORU Medical Systems, Inc. (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, today announced inducement equity awards to Eric Schiller, Chief Technology Officer, pursuant to his previously announced employment agreement with the Company dated as of December 11, 2025. Mr. Schiller was g.

Business Wire • Jan 5, 2026

KRMD Submits 510(k) to Use FreedomEDGE System With Oncology Biologic

KORU Medical filed a 510(k) to use FreedomEDGE for subcutaneous PHESGO delivery, expanding into oncology and simplifying breast cancer care.

Zacks Investment Research • Dec 31, 2025

KORU Medical Systems Announces 510(k) Submission for Clearance of the FreedomEDGE® System with a Commercialized Oncology Biologic

MAHWAH, N.J.--(BUSINESS WIRE)--KORU Medical Systems, Inc. (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, today announced the submission of a 510(k) premarket notification to the U.S. Food and Drug Administration (FDA) seeking clearance for the use of KORU Medical's FreedomEDGE® infusion system to subcutaneously a.

Business Wire • Dec 30, 2025

KORU Medical Systems, Inc. Appoints Eric Schiller as Chief Technology Officer

MAHWAH, N.J.--(BUSINESS WIRE)--KORU Medical Systems, Inc. (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on developing, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, today announced the appointment of Eric Schiller as Chief Technology Officer, effective December 29, 2025. Eric joins KORU Medical with more than 25 years of leadership experience across research & development,.

Business Wire • Dec 16, 2025